Johnson & Johnson Reports Positive Phase 3 Results for Tremfya in Ulcerative Colitis

Johnson & Johnson today announced positive results from the Phase 3 QUASAR trial evaluating guselkumab (Tremfya) in patients with moderately to severely active ulcerative colitis. The trial met its primary endpoint, with significantly more patients achieving clinical remission at week 44 compared to placebo.